Brain cholesterol associated with increased risk of Alzheimer's disease

May 7, 2018, University of Cambridge
Space-filling model of the Cholesterol molecule. Credit: RedAndr/Wikipedia

Researchers have shown how cholesterol—a molecule normally linked with cardiovascular diseases—may also play an important role in the onset and progression of Alzheimer's disease.

The international team, led by the University of Cambridge, have found that in the brain, cholesterol acts as a catalyst which triggers the formation of the toxic clusters of the amyloid-beta protein, which is a central player in the development of Alzheimer's disease.

The results, published in the journal Nature Chemistry, represent another step towards a possible treatment for Alzheimer's disease, which affects millions worldwide. The study's identification of a new pathway in the brain where amyloid-beta sticks together, or aggregates, could represent a new target for potential therapeutics.

It is unclear if the results have any implications for , as cholesterol does not cross the blood-brain barrier. Other studies have also found an association between cholesterol and the condition, since some genes which process cholesterol in the brain have been associated with Alzheimer's disease, but the mechanism behind this link is not known.

The Cambridge researchers found that cholesterol, which is one of the main components of cell walls in neurons, can trigger amyloid-beta molecules to aggregate. The aggregation of amyloid-beta eventually leads to the formation of amyloid plaques, in a toxic chain reaction that leads to the death of brain cells.

While the link between amyloid-beta and Alzheimer's disease is well-established, what has baffled researchers to date is how amyloid-beta starts to aggregate in the brain, as it is typically present at very low levels.

"The levels of amyloid-beta normally found in the brain are about a thousand times lower than we require to observe it aggregating in the laboratory—so what happens in the brain to make it aggregate?" said Professor Michele Vendruscolo of Cambridge's Centre for Misfolding Diseases, who led the research.

Using a kinetic approach developed over the last decade by the Cambridge team and their collaborators at Lund University in Sweden, the researchers found in in vitro studies that the presence of cholesterol in cell membranes can act as a trigger for the aggregation of amyloid-beta.

Since amyloid-beta is normally present in such small quantities in the brain, the molecules don't normally find each other and stick together. Amyloid-beta does attach itself to lipid molecules, however, which are sticky and insoluble. In the case of Alzheimer's disease, the amyloid-beta molecules stick to the lipid cell membranes that contain cholesterol. Once stuck close together on these cell membranes, the amyloid-beta molecules have a greater chance to come into contact with each other and start to aggregate—in fact, the researchers found that cholesterol speeds up the aggregation of amyloid-beta by a factor of 20.

So what, if anything, can be done to control cholesterol in the brain? According to Vendruscolo, it's not cholesterol itself that is the problem. "The question for us now is not how to eliminate cholesterol from the brain, but about how to control cholesterol's role in Alzheimer's disease through the regulation of its interaction with amyloid-beta," he said. "We're not saying that cholesterol is the only trigger for the aggregation process, but it's certainly one of them."

Since it is insoluble, while travelling towards its destination in lipid membranes, cholesterol is never left around by itself, either in the blood or the brain: it has to be carried around by certain dedicated proteins, such as ApoE, a mutation of which has already been identified as a major risk factor for Alzheimer's disease. As we age, these protein carriers, as well as other proteins that control the balance, or homeostasis, of cholesterol in the brain become less effective. In turn, the homeostasis of amyloid-beta and hundreds of other proteins in the brain is broken. By targeting the newly-identified link between amyloid-beta and cholesterol, it could be possible to design therapeutics which maintain cholesterol homeostasis, and consequently amyloid-beta homeostasis, in the brain.

"This work has helped us narrow down a specific question in the field of Alzheimer's research," said Vendruscolo. "We now need to understand in more detail how the balance of is maintained in the in order to find ways to inactivate a trigger of amyloid-beta aggregation."

Explore further: Detecting Alzheimer's disease before it's too late

More information: Johnny Habchi et al, Cholesterol catalyses Aβ42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes, Nature Chemistry (2018). DOI: 10.1038/s41557-018-0031-x

Related Stories

Detecting Alzheimer's disease before it's too late

April 23, 2018
The rate at which the protein beta-amyloid accumulates into the sticky plaques associated with Alzheimer's disease (AD) is already slowing by the time a patient would be considered to have preclinical AD, according to a longitudinal ...

Effects of amyloid beta plaque on different brain cells

April 16, 2018
Amyloid beta, a protein linked with Alzheimer's disease, has different properties in different cell types in the brains of fruit flies. This is the conclusion of a study led by researchers at Linköping University in Sweden. ...

Alzheimer's proteins in ICU survivors

March 29, 2018
While modern medicine has increased the number of people who survive a stay in the Intensive Care Unit (ICU), survivors have a high risk of developing problems with thinking and memory, a phenomenon called cognitive impairment.

'Pac-Man' gene implicated in Alzheimer's disease

July 26, 2016
A gene that protects the brain from the harmful build-up of amyloid-beta, one of the causative proteins implicated in Alzheimer's disease, has been identified as a new target for therapy by NeuRA researchers.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

New research shows how amyloid beta enters brain cells

September 20, 2016
Researchers have known that the peptide amyloid beta plays a role in causing Alzheimer's disease, but they are still working to determine how it becomes toxic.

Recommended for you

Exercise may delay cognitive decline in people with rare Alzheimer's disease

September 25, 2018
For individuals carrying a genetic mutation that causes Alzheimer's disease, engaging in at least 2.5 hours of physical activity per week may have beneficial effects on markers of Alzheimer's disease brain changes and may ...

A biomarker in the brain's circulation system may be Alzheimer's earliest warning

September 24, 2018
USC scientists say Alzheimer's could be diagnosed earlier if scientists focus on an early warning within the brain's circulation system.

In landmark study, doctors say test identifies people most likely to get Alzheimer's

September 24, 2018
The beginning was the worst. It frustrated Janet Parkerson when her father started to forget what he had done that day or the day before.

Study clarifies ApoE4's role in dementia

September 20, 2018
ApoE4, a protein linked to both Alzheimer's disease and a form of dementia caused by damage of blood vessels in the brain, increases the risk of cognitive impairment by reducing the number and responsiveness of blood vessels ...

Machine learning IDs markers to help predict Alzheimer's

September 19, 2018
Nearly 50 million people worldwide have Alzheimer's disease or another form of dementia. These irreversible brain disorders slowly cause memory loss and destroy thinking skills, eventually to such an extent that self-care ...

Discovery could explain failed clinical trials for Alzheimer's, and provide a solution

September 19, 2018
Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trials have failed. The study also identifies a clinically ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.